

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

PLA2G15 RABBIT PAB

货号: S219309

产品全名: PLA2G15 兔多抗

基因符号 ACS; LLPL; LPLA2; LYPLA3; GXVPLA2

UNIPROT ID: Q8NCC3 (Gene Accession - BC011640)

背景: Lysophospholipases are enzymes that act on biological membranes to regulate the multifunctional lysophospholipids. The protein encoded by this gene hydrolyzes lysophosphatidylcholine to glycerophosphorylcholine and a free fatty acid. This enzyme is present in the plasma and thought to be associated with high-density lipoprotein. A later paper contradicts the function of this gene. It demonstrates that this gene encodes a lysosomal enzyme instead of a lysophospholipase and has both calcium-independent phospholipase A2 and transacylase activities.

抗原: Fusion protein of human PLA2G15

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 5000-10000


种属反应性: Rabbit 克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Signal Transduction, Epigenetics and Nuclear Signaling


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219309(PLA2G15 Antibody) at a dilution of 1/65(Cytoplasm)



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 219309(Anti-PLA2G15 Antibody) at dilution 1/65



The image on the left is immunohistochemistry of paraffinembedded Human prostate cancer tissue using 219309(Anti-PLA2G15 Human prostate cancer tissue is first treated with fusion protein and Antibody) at a dilution of 1/65.



In comparision with the IHC on the left, the same paraffin-embedded then with D226268(Anti-PLA2G15 Antibody) at dilution 1/65.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010